Johnson & Johnson CEO warns US tariffs may disrupt drug supply
- QUANTUNG PHARMA
- Apr 14
- 1 min read
Summary
Companies
CEO says tax policies more effective than tariffs to encourage U.S. manufacturing
J&J's shares down marginally, investors cite weak medical device sales
Depression drug Spravato expected to generate $3 billion-3.5 billion in annual sales by 2028
April 15 (Reuters) - Johnson & Johnson (JNJ.N)
, opens new tab Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain disruptions and that favorable tax policies would be a more effective tool to boost U.S. manufacturing capacity of both drugs and medical devices.
Duato, during an investor call to discuss first-quarter results, said that healthcare companies should work with the Trump administration to mitigate supply chain vulnerabilities and prevent any drug shortages that can result from tariffs.
